FIDEXABAN is a potent inhibitor of coagulation factor Xa with anticoagulant activity. Like other factor Xa inhibitors, it prevents thrombus formation.

FLAVAMINE is a diterpenoid alkaloid isolated from the roots of Aconitum fiavum.

PBI 4050, a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, that was developed for managing inflammatory and fibrosis-related diseases. In addition, PBI-4050 may exert antifibrotic activity in the liver through a novel mechanism of action involving modulation of intracellular ATP levels and the LKB1/AMPK/mTOR pathway in stellate cells. This drug participated in clinical trials for the treatment of acute lung injury, cystic fibrosis, diabetic nephropathies; idiopathic pulmonary fibrosis; metabolic syndrome; scleroderma; type 2 diabetes mellitus. Besides, this drug has granted a Rare Pediatric Disease Designation for the treatment of Alström syndrome (AS). PBI-4050 was also previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF) as well as PIM (Promising Innovative Medicine) designation by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of IPF and AS. The FDA grants Rare Pediatric Disease Designations for serious or life-threatening diseases wherein the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups, often called neonates, infants, children, and adolescents. Now Prometic Life Sciences plans to file investigational new drug application for pivotal phase III trial for Alstrom's syndrome in the second half of 2019.

FEPITRIZOL is a hypnotic agent.

Fenalcomine is a coronary vasodilator, cardiotonic and local anesthetic agent. It was studied in the treatment of angina pectoris.

Amiquinsin hydrochloride, 4-amino-6,7-dimethoxquinoline hydrochloride hydrate, is a drug, which exhibits hypotensive activity. Amiquinsin has a more prolonged hypotensive effect than the hydroxyquinoline.

Amphetaminil is chemically an alpha-phenyl-alpha-[(1-methyl-2-phenyl)-ethylamino]-acetonitrile (1), i.e. a derivative of alpha-aminonitrile. It was was developed in the 1970s in Germany and marketed under the brand name Aponeuron. Administration of Aponeuron proved useful in the treatment of children with hyperkinetic syndrome. The subtle and crude motorics improved, symptoms of hyperactivity disappeared and the general school performance of the child improved. Aponeuron was also used in the treatment of disorders of erectile potency, chronic schizophrenia and narcolepsy. In 1974 amphetaminil was included in the class of addictives or habit-forming drugs, although prescription of the drug is not requiring adherence to strict requirements. Nevertheless, it has largely been withdrawn from clinical use.